Clinical-AI innovation company Latent recently announced the completion of a $80M Series A funding round, led by Spark Capital and Transformation Capital, along with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator. This new capital will allow the company to continue expanding upon its mission of delivering accelerated access to life-saving medications and clinical therapies to patients all across the United States.
Latent’s AI-based platform “performs clinical knowledge work by reasoning through patient data, interpreting drug criteria, extracting key evidence, and orchestrating workflows across stakeholders,” including a direct connection between EHR, payer guidelines, pharmacy operations, and more to streamline the overall patient care experience. Going forward, the company is looking to increase the application of its Clinical Reasoning Engine to include the ability to identify when patients should begin treatment therapies, as well as how to ensure that they will be able to continue these therapies for as long as is needed. This paired with an increased focus on deepening relationships with medical providers and facilities, the addition of new talent to the Latent team, and much more, together indicate an exciting future ahead for the medication access platform.
Founded in 2022 by Sriram Somasundaram and Rishabh Jain, Latent has quickly made a name for itself in the medical technology industry with its groundbreaking AI platform built to accelerate and simplify patients’ ability to access life-saving medications and therapies. To date, the company has helped over 2 million patients with its AI-based clinical reasoning engine, and has worked alongside over 45 of the top health systems in the United States. For more information on this story, view the company’s press release below.
See related materials: